Ligand Pharmaceuticals (LGND) closed the last trading session at $87.91, gaining 20.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $116.33 indicates a 32.3% upside potential. The mean estimate comprises three short-term price targets with a standard deviation of $25.11. While the lowest estimate of $95 indicates an 8.1% increase from the current price level, the most optimistic ...